潰瘍性大腸炎(Ulcerative Colitis):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Ulcerative Colitis - Pipeline Review, H2 2014
◆商品コード:GMDHC5672IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年10月30日
◆ページ数:343
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における潰瘍性大腸炎(Ulcerative Colitis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・潰瘍性大腸炎(Ulcerative Colitis)の概要
・潰瘍性大腸炎(Ulcerative Colitis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・潰瘍性大腸炎(Ulcerative Colitis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・潰瘍性大腸炎(Ulcerative Colitis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・潰瘍性大腸炎(Ulcerative Colitis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Ulcerative Colitis – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Ulcerative Colitis – Pipeline Review, H2 2014’, provides an overview of the Ulcerative Colitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Ulcerative Colitis Overview 11
Therapeutics Development 12
Pipeline Products for Ulcerative Colitis – Overview 12
Pipeline Products for Ulcerative Colitis – Comparative Analysis 13
Ulcerative Colitis – Therapeutics under Development by Companies 14
Ulcerative Colitis – Therapeutics under Investigation by Universities/Institutes 20
Ulcerative Colitis – Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Ulcerative Colitis – Products under Development by Companies 25
Ulcerative Colitis – Products under Investigation by Universities/Institutes 32
Ulcerative Colitis – Companies Involved in Therapeutics Development 33
Ajinomoto Pharmaceuticals Co., Ltd. 33
AlphaMab Co., Ltd 34
Altheus Therapeutics, Inc. 35
Am-Pharma B.V. 36
Amgen Inc. 37
Astellas Pharma Inc. 38
AstraZeneca PLC 39
Athersys, Inc. 40
Atlantic Healthcare plc 41
Avaxia Biologics, Inc. 42
Biocon Limited 43
BioLineRx, Ltd. 44
Bristol-Myers Squibb Company 45
Celgene Corporation 46
Celltrion, Inc. 47
ChironWells GmbH 48
Coronado Biosciences, Inc. 49
Cosmo Pharmaceuticals S.p.A 50
Dr. Falk Pharma GmbH 51
Drais Pharmaceuticals, Inc. 52
Effimune SAS 53
Emergent BioSolutions Inc. 54
Enceladus Pharmaceuticals BV 55
Epirus Biopharmaceuticals, Inc. 56
Euroscreen S.A. 57
Farmacija d.o.o. Tuzla 58
Flexion Therapeutics, Inc. 59
Galapagos NV 60
Genentech, Inc. 61
Genfit SA 62
Genor BioPharma Co., Ltd. 63
Gilead Sciences, Inc. 64
GlaxoSmithKline plc 65
GT Biologics Limited 66
GW Pharmaceuticals plc 67
Harbor Therapeutics, Inc. 68
iCo Therapeutics Inc. 69
InDex Pharmaceuticals AB 70
INOXIA Lifesciences GmbH 71
Invion Limited 72
Johnson & Johnson 73
Kaken Pharmaceutical Co., Ltd. 74
LIPID THERAPEUTICS GmbH 75
LTT Bio-Pharma Co., Ltd. 76
Medestea Research & Production S.p.A. 77
Morphotek, Inc. 78
NasVax Ltd. 79
Nogra Pharma Limited 80
Oncobiologics, Inc. 81
Pfizer Inc. 82
Pluristem Therapeutics Inc. 83
ProtAb Ltd 84
Qu Biologics Inc. 85
Receptos, Inc. 86
Sandoz Inc. 87
Sanofi 88
Sigmoid Pharma Limited 89
Stelic Institute & Co. 90
sterna biologicals Gmbh & Co KG 91
Synergy Pharmaceuticals, Inc. 92
Takeda Pharmaceutical Company Limited 93
TiGenix NV 94
Tillotts Pharma AG 95
Trino Therapeutics Ltd 96
Vascular Biogenics Ltd. 97
Ventria Bioscience 98
Zyngenia, Inc. 99
Ulcerative Colitis – Therapeutics Assessment 100
Assessment by Monotherapy Products 100
Assessment by Combination Products 101
Assessment by Target 102
Assessment by Mechanism of Action 106
Assessment by Route of Administration 109
Assessment by Molecule Type 111
Drug Profiles 113
(mesalamine + N-acetylcysteine) – Drug Profile 113
(metenkefalin + tridecactide) – Drug Profile 115
AB-0045 – Drug Profile 116
abrilumab – Drug Profile 117
ABS-11 – Drug Profile 119
adalimumab biosimilar – Drug Profile 120
adalimumab biosimilar – Drug Profile 122
adalimumab biosimilar – Drug Profile 123
adalimumab biosimilar – Drug Profile 124
adalimumab biosimilar – Drug Profile 125
adalimumab biosimilar – Drug Profile 126
adalimumab biosimilar – Drug Profile 127
adalimumab biosimilar – Drug Profile 128
adalimumab biosimilar – Drug Profile 129
AJM-300 – Drug Profile 130
alicaforsen sodium – Drug Profile 132
Anatabine – Drug Profile 133
Anti-CD3 Oral Immunotherapy – Drug Profile 134
Antibodies to Target Metallothioneins for Ulcerative Colitis and Crohns Disease – Drug Profile 136
apremilast – Drug Profile 137
ASP-3291 – Drug Profile 139
AVX-470 – Drug Profile 140
AW/EPO-002 – Drug Profile 141
AW/EPO-003 – Drug Profile 142
AW/EPOPD-01 – Drug Profile 143
AW/EPOPD-02 – Drug Profile 144
AW/EPOPD-06 – Drug Profile 145
bertilimumab – Drug Profile 146
BL-7040 – Drug Profile 148
BLI-1006 – Drug Profile 151
budesonide – Drug Profile 152
budesonide ER – Drug Profile 155
budesonide ER – Drug Profile 157
CNDO-201 – Drug Profile 159
Cx-602 – Drug Profile 161
cyclosporine CR – Drug Profile 162
DIMS-0150 – Drug Profile 163
Drugs for Ulcerative Colitis – Drug Profile 165
Drugs to Inhibit TNFR25 for Gastrointestinal Disorders – Drug Profile 166
eldelumab – Drug Profile 167
enalaprilat – Drug Profile 169
ES-210 – Drug Profile 171
ESN-282 – Drug Profile 172
etrolizumab – Drug Profile 173
FX-003 – Drug Profile 175
GED-0507 – Drug Profile 176
GFT-505 – Drug Profile 177
GLPG-0974 – Drug Profile 180
GS-5745 – Drug Profile 181
GSK-1399686 – Drug Profile 182
GWP-42003 – Drug Profile 183
HE-3286 – Drug Profile 185
hyaluronate sodium – Drug Profile 187
IAC VITA – Drug Profile 188
infliximab – Drug Profile 190
infliximab biosimilar – Drug Profile 192
infliximab biosimilar – Drug Profile 194
infliximab biosimilar – Drug Profile 195
INV-103 – Drug Profile 196
INV-88 – Drug Profile 198
KAG-308 – Drug Profile 199
KANAb-071 – Drug Profile 200
Leukothera – Drug Profile 201
Low Molecular Weight Heparin – Drug Profile 202
LT-02 – Drug Profile 203
MD-707 – Drug Profile 204
mesalamine – Drug Profile 205
mesalamine – Drug Profile 206
mesalamine CR – Drug Profile 207
mesalamine ER – Drug Profile 208
Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis and Inflammatory Disease – Drug Profile 210
MultiStem – Drug Profile 211
naltrexone – Drug Profile 214
Nanocort – Drug Profile 215
ONS-3015 – Drug Profile 217
PC-SOD – Drug Profile 218
peficitinib – Drug Profile 219
Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn’s Disease – Drug Profile 220
PF-00547659 – Drug Profile 221
PH-44 – Drug Profile 223
PH-46A – Drug Profile 224
PH-5 – Drug Profile 225
Prozumab – Drug Profile 226
QBECO – Drug Profile 227
Recombinant Human Alkaline Phosphatase – Drug Profile 229
Rosburix – Drug Profile 231
RPC-1063 – Drug Profile 232
SAR-252067 – Drug Profile 234
SB-012 – Drug Profile 235
SD-010 – Drug Profile 236
Small Molecule for Ulcerative Colitis and Inflammation – Drug Profile 237
Small Molecule to Agonize OP3 Receptor for Inflammatory Bowel Diseases – Drug Profile 238
Small Molecules for Gastrointestinal Disorders – Drug Profile 239
Small Molecules to Inhibit IL-13 for Inflammatory Bowel Disease and Ulcerative Colitis – Drug Profile 240
Small Molecules to Target IL-13 for Inflammatory Bowel Disease and Ulcerative Colitis – Drug Profile 241
SP-333 – Drug Profile 242
Stem Cell Therapy for Inflammatory Bowel Disease – Drug Profile 243
STNM-01 – Drug Profile 244
TAK-114 – Drug Profile 245
tofacitinib – Drug Profile 247
VB-201 – Drug Profile 251
VEDA-1209 – Drug Profile 253
vedolizumab – Drug Profile 254
VEN-120 – Drug Profile 256
Ulcerative Colitis – Recent Pipeline Updates 257
Ulcerative Colitis – Dormant Projects 323
Ulcerative Colitis – Discontinued Products 326
Ulcerative Colitis – Product Development Milestones 327
Featured News & Press Releases 327
Appendix 335
Methodology 335
Coverage 335
Secondary Research 335
Primary Research 335
Expert Panel Validation 335
Contact Us 336
Disclaimer 336

[List of Tables]
Number of Products under Development for Ulcerative Colitis, H2 2014 19
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H2 2014 20
Number of Products under Development by Companies, H2 2014 22
Number of Products under Development by Companies, H2 2014 (Contd..1) 23
Number of Products under Development by Companies, H2 2014 (Contd..2) 24
Number of Products under Development by Companies, H2 2014 (Contd..3) 25
Number of Products under Development by Companies, H2 2014 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H2 2014 27
Comparative Analysis by Late Stage Development, H2 2014 28
Comparative Analysis by Clinical Stage Development, H2 2014 29
Comparative Analysis by Early Stage Development, H2 2014 30
Comparative Analysis by Unknown Stage Development, H2 2014 31
Products under Development by Companies, H2 2014 32
Products under Development by Companies, H2 2014 (Contd..1) 33
Products under Development by Companies, H2 2014 (Contd..2) 34
Products under Development by Companies, H2 2014 (Contd..3) 35
Products under Development by Companies, H2 2014 (Contd..4) 36
Products under Development by Companies, H2 2014 (Contd..5) 37
Products under Development by Companies, H2 2014 (Contd..6) 38
Products under Investigation by Universities/Institutes, H2 2014 39
Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H2 2014 40
Ulcerative Colitis - Pipeline by AlphaMab Co., Ltd, H2 2014 41
Ulcerative Colitis - Pipeline by Altheus Therapeutics, Inc., H2 2014 42
Ulcerative Colitis - Pipeline by Am-Pharma B.V., H2 2014 43
Ulcerative Colitis - Pipeline by Amgen Inc., H2 2014 44
Ulcerative Colitis - Pipeline by Astellas Pharma Inc., H2 2014 45
Ulcerative Colitis - Pipeline by AstraZeneca PLC, H2 2014 46
Ulcerative Colitis - Pipeline by Athersys, Inc., H2 2014 47
Ulcerative Colitis - Pipeline by Atlantic Healthcare plc, H2 2014 48
Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H2 2014 49
Ulcerative Colitis - Pipeline by Biocon Limited, H2 2014 50
Ulcerative Colitis - Pipeline by BioLineRx, Ltd., H2 2014 51
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2014 52
Ulcerative Colitis - Pipeline by Celgene Corporation, H2 2014 53
Ulcerative Colitis - Pipeline by Celltrion, Inc., H2 2014 54
Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2014 55
Ulcerative Colitis - Pipeline by Coronado Biosciences, Inc., H2 2014 56
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2014 57
Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2014 58
Ulcerative Colitis - Pipeline by Drais Pharmaceuticals, Inc., H2 2014 59
Ulcerative Colitis - Pipeline by Effimune SAS, H2 2014 60
Ulcerative Colitis - Pipeline by Emergent BioSolutions Inc., H2 2014 61
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2014 62
Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 63
Ulcerative Colitis - Pipeline by Euroscreen S.A., H2 2014 64
Ulcerative Colitis - Pipeline by Farmacija d.o.o. Tuzla, H2 2014 65
Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H2 2014 66
Ulcerative Colitis - Pipeline by Galapagos NV, H2 2014 67
Ulcerative Colitis - Pipeline by Genentech, Inc., H2 2014 68
Ulcerative Colitis - Pipeline by Genfit SA, H2 2014 69
Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H2 2014 70
Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H2 2014 71
Ulcerative Colitis - Pipeline by GlaxoSmithKline plc, H2 2014 72
Ulcerative Colitis - Pipeline by GT Biologics Limited, H2 2014 73
Ulcerative Colitis - Pipeline by GW Pharmaceuticals plc, H2 2014 74
Ulcerative Colitis - Pipeline by Harbor Therapeutics, Inc., H2 2014 75
Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H2 2014 76
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H2 2014 77
Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H2 2014 78
Ulcerative Colitis - Pipeline by Invion Limited, H2 2014 79
Ulcerative Colitis - Pipeline by Johnson & Johnson, H2 2014 80
Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2014 81
Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H2 2014 82
Ulcerative Colitis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014 83
Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H2 2014 84
Ulcerative Colitis - Pipeline by Morphotek, Inc., H2 2014 85
Ulcerative Colitis - Pipeline by NasVax Ltd., H2 2014 86
Ulcerative Colitis - Pipeline by Nogra Pharma Limited, H2 2014 87
Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H2 2014 88
Ulcerative Colitis - Pipeline by Pfizer Inc., H2 2014 89
Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H2 2014 90
Ulcerative Colitis - Pipeline by ProtAb Ltd, H2 2014 91
Ulcerative Colitis - Pipeline by Qu Biologics Inc., H2 2014 92
Ulcerative Colitis - Pipeline by Receptos, Inc., H2 2014 93
Ulcerative Colitis - Pipeline by Sandoz Inc., H2 2014 94
Ulcerative Colitis - Pipeline by Sanofi, H2 2014 95
Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H2 2014 96
Ulcerative Colitis - Pipeline by Stelic Institute & Co., H2 2014 97
Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2014 98
Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H2 2014 99
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 100
Ulcerative Colitis - Pipeline by TiGenix NV, H2 2014 101
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H2 2014 102
Ulcerative Colitis - Pipeline by Trino Therapeutics Ltd, H2 2014 103
Ulcerative Colitis - Pipeline by Vascular Biogenics Ltd., H2 2014 104
Ulcerative Colitis - Pipeline by Ventria Bioscience, H2 2014 105
Ulcerative Colitis - Pipeline by Zyngenia, Inc., H2 2014 106
Assessment by Monotherapy Products, H2 2014 107
Assessment by Combination Products, H2 2014 108
Number of Products by Stage and Target, H2 2014 110
Number of Products by Stage and Mechanism of Action, H2 2014 114
Number of Products by Stage and Route of Administration, H2 2014 117
Number of Products by Stage and Molecule Type, H2 2014 119
Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H2 2014 264
Ulcerative Colitis - Dormant Projects, H2 2014 330
Ulcerative Colitis - Discontinued Products, H2 2014 333

[List of Figures]
Number of Products under Development for Ulcerative Colitis, H2 2014 19
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H2 2014 20
Number of Products under Development by Companies, H2 2014 21
Number of Products under Investigation by Universities/Institutes, H2 2014 27
Comparative Analysis by Late Stage Development, H2 2014 28
Comparative Analysis by Clinical Stage Development, H2 2014 29
Comparative Analysis by Early Stage Products, H2 2014 30
Comparative Analysis by Unknown Stage Development, H2 2014 31
Assessment by Monotherapy Products, H2 2014 107
Assessment by Combination Products, H2 2014 108
Number of Products by Top 10 Targets, H2 2014 109
Number of Products by Stage and Top 10 Targets, H2 2014 109
Number of Products by Top 10 Mechanism of Actions, H2 2014 113
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 113
Number of Products by Top 10 Routes of Administration, H2 2014 116
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 116
Number of Products by Top 10 Molecule Types, H2 2014 118
Number of Products by Stage and Top 10 Molecule Types, H2 2014 118

【掲載企業】

Ajinomoto Pharmaceuticals Co., Ltd.
AlphaMab Co., Ltd
Altheus Therapeutics, Inc.
Am-Pharma B.V.
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Athersys, Inc.
Atlantic Healthcare plc
Avaxia Biologics, Inc.
Biocon Limited
BioLineRx, Ltd.
Bristol-Myers Squibb Company
Celgene Corporation
Celltrion, Inc.
ChironWells GmbH
Coronado Biosciences, Inc.
Cosmo Pharmaceuticals S.p.A
Dr. Falk Pharma GmbH
Drais Pharmaceuticals, Inc.
Effimune SAS
Emergent BioSolutions Inc.
Enceladus Pharmaceuticals BV
Epirus Biopharmaceuticals, Inc.
Euroscreen S.A.
Farmacija d.o.o. Tuzla
Flexion Therapeutics, Inc.
Galapagos NV
Genentech, Inc.
Genfit SA
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc
GT Biologics Limited
GW Pharmaceuticals plc
Harbor Therapeutics, Inc.
iCo Therapeutics Inc.
InDex Pharmaceuticals AB
INOXIA Lifesciences GmbH
Invion Limited
Johnson & Johnson
Kaken Pharmaceutical Co., Ltd.
LIPID THERAPEUTICS GmbH
LTT Bio-Pharma Co., Ltd.
Medestea Research & Production S.p.A.
Morphotek, Inc.
NasVax Ltd.
Nogra Pharma Limited
Oncobiologics, Inc.
Pfizer Inc.
Pluristem Therapeutics Inc.
ProtAb Ltd
Qu Biologics Inc.
Receptos, Inc.
Sandoz Inc.
Sanofi
Sigmoid Pharma Limited
Stelic Institute & Co.
sterna biologicals Gmbh & Co KG
Synergy Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
TiGenix NV
Tillotts Pharma AG
Trino Therapeutics Ltd
Vascular Biogenics Ltd.
Ventria Bioscience
Zyngenia, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[潰瘍性大腸炎(Ulcerative Colitis):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆